Cosmos Health Inc. COSM

Cosmos Health adds 5.2 million units via new five-year agreements with Target Pharma, lifting orderbook past 32.7 million units, up 31% since June. New multi-year contracts and 31% orderbook growth signal major revenue expansion and stronger market position.

Cosmos Health tokenizes CCX0722 intellectual property in non-dilutive structure targeting $562 billion weight-management market. IP tokenization delivers non-dilutive funding for entry into massive weight-management sector, likely strengthening financials and growth trajectory.

Cosmos Health secures an additional 2.5 million units under a new five-year contract manufacturing agreement with Viofar, bringing the total orderbook beyond 27.5 million units. New five-year contract adds 2.5 million units and expands total orderbook past 27.5 million, strengthening future manufacturing revenue.

COSM expands its market presence and accelerates growth initiatives. Market expansion and accelerated growth represent major strategic moves that significantly alter Cosmos Health Inc.'s trajectory and investor sentiment.

Cosmos Health launches C-ScrubVet in the UK, entering the $69 billion global animal health market. Product launch into large animal health market represents major strategic expansion for Cosmos Health.

Cosmos Health retires its $8M ATW convertible note one year ahead of maturity, strengthening its balance sheet, streamlining capital structure, and eliminating further share dilution from conversions. Early debt retirement improves financial stability and shields shareholders from dilution.

Cosmos Health projects over $6M annual revenue and $4.3M gross profit from Oliv18™ in U.S. cardiovascular health and antioxidant categories. Oliv18™ revenue and profit projections signal major expansion in cardiovascular and antioxidant sectors.

Cosmos Health enters Saudi Arabia via exclusive distribution deal with Innova Healthcare, securing initial order of 126,000 Sky Premium Life units and projecting over 5 million units over five years. Exclusive Saudi market entry with large initial and long-term orders drives significant revenue growth and geographic expansion for Cosmos Health.

Cosmos Health achieved record Q2 2026 revenue of $19.0M, up 29%, and H1 revenue of $36.9M, up 30%. Q2 adjusted gross profit rose 58%. Total liabilities dropped 13% while stockholders' equity climbed 12%. A $5M share repurchase program is underway. Strong revenue and profit growth combined with lower liabilities, higher equity, and share buybacks signal major positive shifts in financial position and investor sentiment.

Cosmos Health Inc. (COSM) produced a stellar quarter with strong results. Strong quarterly performance signals major positive shift in financial trajectory and investor sentiment.

Cosmos Health Inc. (COSM) advances its technology-driven transformation by launching an AI-enabled subscription platform across B2C and B2B channels. AI-enabled subscription platform launch marks a major strategic technology initiative expected to significantly alter Cosmos Health's trajectory and market positioning.

Cosmos Health Inc. reports substantial growth and launches a share buyback program. Growth reports paired with buybacks can lift near-term sentiment and valuation without altering long-term fundamentals.

Cosmos Health expands Pharma Cell partnership in Albania with annualized orders projected to exceed 54,000 units. Partnership expansion projects over 54,000 annualized units in orders indicating material revenue upside.

Cosmos Health Inc. surpassed 4.5 million shares in its buyback program and continues repurchasing shares on the open market. Ongoing buybacks exceeding 4.5 million shares support stock price and signal management confidence without transforming core operations.

Cosmos Health Inc. reached 4.36 million shares repurchased under its buyback program and continues open-market purchases. Repurchase of 4.36 million shares provides direct share-price support and signals management confidence.

Cosmos Health Inc. partners with Libytec to commercialize DIABIT-IS X prescription medicine in Greece, accelerating its prescription medicine strategy. Partnership advances Cosmos Health prescription medicine expansion via DIABIT-IS X commercialization in Greece.

Cosmos Health launches subscription model. Subscription model introduces recurring revenue potential but lacks scale to fundamentally shift company trajectory.

Cosmos Health Inc. buyback exceeds 4 million shares with ongoing open market repurchases. Share repurchases over 4 million support stock price and shareholder value without altering core operations.

Cosmos Health reports preliminary record Q2 and H1 2026 revenue, up over 30 percent year-over-year. The company continues open market share repurchases. Record revenue growth combined with share buybacks signals strong performance and supports positive market revaluation.

Cosmos Health Inc. expands its share buyback program to 3.87 million shares and continues open-market repurchases. Share buybacks can support stock price and signal management confidence but rarely transform company fundamentals.

Cosmos Health Inc. authorized a share repurchase program of up to $5 million. A $5 million share repurchase authorization can moderately support stock price and investor sentiment through reduced shares outstanding.

Cosmos Health Inc. formed a distribution partnership in Qatar. CEO described the deal as a high-impact partnership for the nano-cap company. New Qatar distribution tie-up may boost COSM regional sales but remains a single non-transformative step for the nano-cap firm.

Cosmos Health signed distribution agreement with IMC, owner of Qatar's largest pharmacy chain, and secured initial purchase order for 31,000 Sky Premium Life units. New Qatar distribution deal with sizable initial order expands market reach but represents limited overall trajectory shift.

Cosmos Health advances international patent application for proprietary hydrogel weight management platform in U.S., Europe, Australia, and Canada. Patent advancement supports product innovation in weight management but remains early-stage without immediate commercial effects.

Cosmos Health’s C-Sept PRO is expanding across major Greek public and private hospitals, with annualized sales projected above $1.3 million at roughly 72% gross margin. New product adoption and sales forecast point to meaningful revenue growth for Cosmos Health.

Cosmos Health Inc. signed an agreement to deploy an AI-powered call center optimizing order intake, customer communications, and operating efficiency. AI call center deployment targets efficiency gains in order processing and customer interactions for Cosmos Health.

Cosmos Health has expanded its contract manufacturing orderbook to over 25 million units, positioning the division to generate over $10 million in recurring annual profit. Contract manufacturing orderbook expansion to over 25 million units enables more than $10 million in recurring annual profit.

CosmoFarm posted record Q2 2026 revenue above $15 million for a $60+ million annualized run-rate. The company added over 80 pharmacies while expanding AI automation and facility capacity. Record revenue combined with pharmacy network growth and AI expansion points to material upside in Cosmos Health revenue trajectory and market position.

Cosmos Health enters the $163 billion global skincare market with sales already underway in the United States. Entry into $163B skincare market with active US sales constitutes major strategic expansion with direct revenue potential.

Cosmos Health Inc. signed a 2.86 million-unit contract manufacturing agreement with Pharmex S.A. for three dermatological products. Deal expands Cosmos Health manufacturing output and revenue potential in dermatology without transforming core operations.